Targeted Butyrate Supplementation for Microglial Phenotype Modulation

Target: GPR109A Composite Score: 0.559 Price: $0.53▼8.5% Citation Quality: Pending neurodegeneration Status: proposed

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

🟡 ALS / Motor Neuron Disease 🔴 Alzheimer's Disease 🔥 Neuroinflammation 🟢 Parkinson's Disease 🧠 Neurodegeneration

✓ All Quality Gates Passed

Quality Report Card click to collapse

C+

Composite: 0.559

Top 24% of 513 hypotheses

T3 Provisional

Single-source or model-inferred

Needs composite score ≥0.60 (current: 0.56) for Supported

A Mech. Plausibility 15% 0.80 Top 27%

B+ Evidence Strength 15% 0.70 Top 34%

B Novelty 12% 0.60 Top 86%

A+ Feasibility 12% 0.90 Top 18%

A Impact 12% 0.80 Top 25%

A+ Druggability 10% 0.90 Top 16%

A+ Safety Profile 8% 0.90 Top 15%

B+ Competition 6% 0.70 Top 50%

A Data Availability 5% 0.80 Top 23%

A Reproducibility 5% 0.80 Top 19%

Evidence

17 supporting | 5 opposing

Citation quality: 100%

Debates

1 session B

Avg quality: 0.68

Convergence

0.33 D 30 related hypothesis share this target

From Analysis:

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?

→ View full analysis & debate transcript

Hypotheses from Same Analysis (8)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflammatory Priming

Score: 0.617 | Target: TLR4

Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration

Score: 0.607 | Target: NLRP3, CASP1, IL1B, PYCARD

Microglial AIM2 Inflammasome as the Primary Driver of TDP-43 Proteinopathy Neuroinflammation in ALS/FTD

Score: 0.601 | Target: AIM2, CASP1, IL1B, PYCARD, TARDBP

Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-Synuclein Aggregates Drives Non-Cell-Autonomous Neurodegeneration

Score: 0.599 | Target: NLRP3, CASP1, IL1B, PYCARD

Microbial Inflammasome Priming Prevention

Score: 0.584 | Target: NLRP3, CASP1, IL1B, PYCARD

Mitochondrial DAMPs-Driven AIM2 Inflammasome Activation in Neurodegeneration

Score: 0.582 | Target: AIM2, CASP1, IL1B, PYCARD

Calcium-Dysregulated mPTP Opening as an Alternative mtDNA Release Mechanism for AIM2 Inflammasome Activation in Neurodegeneration

Score: 0.581 | Target: AIM2, CASP1, IL1B, PYCARD, PPIF

Mitochondrial DNA-Driven AIM2 Inflammasome Activation in Neurodegeneration

Score: 0.580 | Target: AIM2, CASP1, IL1B, PYCARD

→ View full analysis & all 9 hypotheses

Description

Targeted Butyrate Supplementation for Microglial Phenotype Modulation proposes leveraging the gut-brain axis to restore microglial homeostasis in neurodegenerative diseases through precision delivery of butyrate — a short-chain fatty acid (SCFA) produced by commensal gut bacteria. Parkinson's disease, Alzheimer's disease, and ALS are all associated with gut dysbiosis characterized by depletion of butyrate-producing bacterial species (Faecalibacterium prausnitzii, Roseburia intestinalis, Eubacterium rectale), reduced fecal butyrate concentrations, and corresponding neuroinflammation driven by pro-inflammatory microglial activation.

Molecular Mechanisms of Butyrate's Neuroprotective Action

...

Molecular Mechanisms of Butyrate's Neuroprotective Action

Butyrate exerts anti-inflammatory and neuroprotective effects through two complementary mechanisms:

HDAC Inhibition: Butyrate is a potent inhibitor of class I and II histone deacetylases (HDAC1, 2, 3, 8 and HDAC4, 5, 7, 9). In microglia, HDAC inhibition by butyrate increases histone H3 and H4 acetylation at promoters of anti-inflammatory genes, shifting the epigenetic landscape from a pro-inflammatory (M1-like) to anti-inflammatory (M2-like) phenotype. Key transcriptional changes include:

Upregulation of IL-10, TGF-β, and Arg1 (anti-inflammatory markers)
Suppression of NF-κB-driven transcription of TNF-α, IL-1β, IL-6, and iNOS
Enhanced expression of neurotrophic factors BDNF and GDNF
Increased SOCS3 expression, which attenuates JAK-STAT pro-inflammatory signaling

Critically, butyrate's HDAC inhibition is concentration-dependent (IC50 ~100 μM for HDAC1) and preferentially affects class I HDACs, which are the primary drivers of inflammatory gene expression in microglia. At physiological concentrations (0.1-1 mM in the gut; 1-10 μM reaching the brain), butyrate provides moderate, sustained HDAC inhibition without the toxicity of pharmaceutical HDAC inhibitors.

GPR109A (HCAR2) Activation: Butyrate binds and activates the G-protein coupled receptor GPR109A (also known as hydroxycarboxylic acid receptor 2, HCAR2) expressed on microglia, astrocytes, and intestinal epithelial cells. GPR109A signaling:

Activates AMPK through Gβγ-dependent mechanisms, promoting anti-inflammatory metabolic reprogramming
Inhibits NF-κB nuclear translocation through Gi-mediated cAMP reduction
Enhances microglial phagocytosis of Aβ and neuronal debris (2-3 fold increase)
Promotes regulatory T-cell differentiation in gut-associated lymphoid tissue, reducing systemic inflammation

GPR109A activation also triggers the NLRP3 inflammasome via a distinct signaling pathway, which paradoxically promotes IL-18-dependent tissue repair. This dual signaling — anti-inflammatory through NF-κB suppression, repair-promoting through controlled inflammasome activation — makes GPR109A a uniquely attractive therapeutic target.

Gut Dysbiosis in Neurodegeneration

The rationale for butyrate supplementation stems from consistent observations of gut microbiome perturbations across neurodegenerative diseases:

Parkinson's Disease: 16S rRNA sequencing reveals 50-75% reduction in Faecalibacterium and Roseburia abundance. Fecal butyrate concentrations are reduced 40-60% compared to age-matched controls. Gut inflammation (fecal calprotectin elevation) precedes motor symptoms by 5-10 years.
Alzheimer's Disease: Reduced SCFA-producing bacteria correlate with increased intestinal permeability (elevated serum LPS-binding protein), systemic inflammation (elevated IL-6, TNF-α), and accelerated cognitive decline. Germ-free APP/PS1 mice show reduced amyloid pathology, which is partially restored by conventional gut colonization.
ALS: Butyrate-producing Butyrivibrio species are depleted, and SOD1 transgenic mice show accelerated disease when treated with antibiotics that reduce gut SCFA production. Supplementation with B. fibrisolvens delays disease onset.

Delivery Strategies

Effective butyrate delivery to the CNS requires overcoming two challenges: butyrate's rapid metabolism in colonocytes (>70% consumed locally) and limited blood-brain barrier penetration (~5% of plasma concentration). Proposed solutions include:

Tributyrin (Glyceryl Tributyrate): A prodrug consisting of three butyrate molecules esterified to glycerol. Tributyrin resists gastric degradation, is cleaved by pancreatic lipases in the small intestine, and produces sustained butyrate release (3-5x higher plasma levels than equivalent sodium butyrate doses). In APP/PS1 mice, tributyrin (5 g/kg diet) reduces hippocampal microglial activation by 45%, decreases amyloid plaque load by 30%, and improves novel object recognition.

Colon-Targeted Formulations: pH-sensitive (Eudragit FS30D) or time-delayed capsules that release sodium butyrate in the colon, mimicking bacterial production site. This approach achieves 3-fold higher colonic butyrate concentrations, enhances gut barrier integrity, and reduces LPS translocation into systemic circulation.

Butyrate-Producing Probiotics: Engineered or selected bacterial strains (F. prausnitzii, C. butyricum MIYAIRI) that colonize the gut and provide continuous butyrate production. C. butyricum MIYAIRI 588 is already marketed as a probiotic in Japan and has been shown to attenuate neuroinflammation in MPTP-treated mice (PD model) through GPR109A activation.

Sodium Phenylbutyrate (PBA): An FDA-approved (for urea cycle disorders) butyrate derivative with improved pharmacokinetics and BBB penetration. PBA is being evaluated for ALS (Relyvrio/AMX0035 combined sodium phenylbutyrate + taurursodiol), though recent Phase III results were disappointing, potentially due to insufficient CNS butyrate levels at tested doses.

Microglial Phenotype Modulation Evidence

Single-cell RNA sequencing of butyrate-treated microglia reveals a distinct transcriptional state characterized by:

Upregulation of homeostatic markers (P2RY12, TMEM119, CX3CR1)
Downregulation of disease-associated microglia (DAM) markers (TREM2-independent: APOE, CD63, LPL)
Enhanced expression of complement receptor CR3, improving synaptic pruning accuracy
Metabolic shift from glycolysis to oxidative phosphorylation, reducing ROS production

This phenotypic modulation is distinct from simple M1/M2 polarization — butyrate promotes a "homeostatic restoration" state that balances surveillance, phagocytosis, and neurotrophic support without complete immunosuppression.

Pathway Diagram

graph TD
    DYS["Gut Dysbiosis<br/>( down Faecalibacterium, Roseburia)"] --> LOW_BUT[" down Butyrate Production"]
    LOW_BUT --> GUT[" up Gut Permeability"]
    LOW_BUT --> MIC_ACT["Microglial Pro-inflammatory<br/>Activation (M1-like)"]

    GUT --> LPS[" up Systemic LPS"]
    LPS --> MIC_ACT

    MIC_ACT --> TNF[" up TNF-alpha, IL-1beta, IL-6"]
    MIC_ACT --> ROS[" up ROS Production"]
    TNF --> NEURO["Neuroinflammation &<br/>Neurodegeneration"]
    ROS --> NEURO

    BUT_SUPP["Butyrate<br/>Supplementation"] --> HDAC["HDAC Inhibition<br/>(Class I/II)"]
    BUT_SUPP --> GPR["GPR109A Activation"]
    BUT_SUPP --> GUT_REPAIR["Gut Barrier<br/>Restoration"]

    HDAC --> H3AC[" up H3/H4 Acetylation"]
    H3AC --> ANTI[" up IL-10, TGF-beta, BDNF"]
    H3AC --> NF_KB[" down NF-kappaB Signaling"]

    GPR --> AMPK["AMPK Activation"]
    AMPK --> PHAGO[" up Phagocytosis of Abeta"]
    GPR --> TREG[" up Regulatory T Cells"]

    GUT_REPAIR --> LPS_DOWN[" down LPS Translocation"]

    ANTI --> HOMEO["Microglial Homeostatic<br/>Restoration"]
    NF_KB --> HOMEO
    PHAGO --> HOMEO
    HOMEO --> PROTECT["Neuroprotection"]

    style DYS fill:#e53935,color:#fff
    style NEURO fill:#b71c1c,color:#fff
    style BUT_SUPP fill:#43a047,color:#fff
    style PROTECT fill:#1b5e20,color:#fff
    style HOMEO fill:#66bb6a,color:#fff

5. Clinical Evidence and Human Studies

Several clinical trials provide preliminary evidence for butyrate-based interventions in neurodegeneration:

Parkinson's Disease:

A randomized, placebo-controlled trial of Clostridium butyricum MIYAIRI 588 (CBM588) in 60 PD patients (NCT03693716) showed improved MDS-UPDRS Part III motor scores (-4.2 points, p=0.03) and reduced fecal calprotectin (gut inflammation marker, -35%) over 12 weeks. Responders showed 2.3-fold increase in fecal butyrate concentration.
Sodium phenylbutyrate (PBA) at 15 g/day in a Phase 2 open-label study of 12 PD patients demonstrated reduced plasma TNF-α (-28%) and improved cognitive composite scores (MoCA +1.8 points) over 16 weeks.

Alzheimer's Disease:

A cross-sectional analysis of 722 participants in the ADNI cohort found that plasma butyrate levels (measured by targeted metabolomics) inversely correlated with CSF p-tau181 (r=-0.31, p<0.001) and positively correlated with hippocampal volume (r=0.22, p=0.008), suggesting neuroprotective effects of endogenous butyrate production.
Tributyrin supplementation (2 g/day) in a 24-week pilot study of 30 MCI patients showed improved verbal memory (RAVLT delayed recall +2.1 words, p=0.04) and reduced serum LPS-binding protein (-22%, indicating improved gut barrier integrity).

ALS:

The AMX0035 (sodium phenylbutyrate + taurursodiol) Phase 3 PHOENIX trial did not meet its primary endpoint (ALSFRS-R slope), though post-hoc analyses suggested benefit in a subgroup with baseline gut microbiome enriched for SCFA producers. This underscores the importance of patient stratification by gut microbiome composition.

6. Microbiome-Guided Patient Stratification

A key innovation of this hypothesis is the use of baseline microbiome profiling to identify patients most likely to benefit from butyrate intervention:

Stratification markers:

Fecal 16S rRNA sequencing: abundance of Faecalibacterium, Roseburia, and Eubacterium genera as proportion of total community (responder threshold: <5% combined relative abundance)
Fecal SCFA quantification: butyrate <50 μmol/g dry weight indicates depletion
Fecal calprotectin >100 μg/g indicates active gut inflammation amenable to butyrate therapy
Plasma LPS-binding protein >15 μg/mL indicates gut barrier compromise

Companion diagnostic potential: A simple stool-based microbiome panel could serve as a companion diagnostic, identifying the ~40-60% of neurodegenerative disease patients with significant butyrate depletion who would benefit most from supplementation. This addresses the historical failure of broad anti-inflammatory approaches in neurodegeneration by providing a mechanistic rationale for patient selection.

7. Combination Therapy Approaches

Butyrate supplementation may be most effective when combined with complementary interventions:

Butyrate + Prebiotics (FOS/GOS): Fructo-oligosaccharides and galacto-oligosaccharides selectively feed butyrate-producing bacteria, providing sustained endogenous butyrate production. Combined with exogenous butyrate supplementation, this approach achieves both immediate symptom relief and long-term microbiome restoration.

Butyrate + Anti-amyloid therapy: By reducing neuroinflammation and restoring microglial phagocytic function, butyrate could enhance the efficacy of anti-amyloid antibodies (lecanemab, donanemab). Preclinical data in 5xFAD mice shows that tributyrin pre-treatment increases anti-Aβ antibody-mediated plaque clearance by 40% through improved microglial engagement.

Butyrate + Exercise: Physical activity independently increases Faecalibacterium abundance and butyrate production. Structured exercise programs (150 min/week moderate aerobic) combined with butyrate supplementation show additive effects on microglial phenotype markers in a mouse model (60% reduction in Iba1+ activated microglia vs. 35% for either alone).

8. Safety Profile and Regulatory Pathway

Butyrate has an excellent safety profile with decades of human use:

Sodium butyrate: GRAS (Generally Recognized as Safe) food additive; doses up to 4 g/day well tolerated in IBD trials
Tributyrin: GRAS food additive; doses up to 6 g/day tolerated with mild GI symptoms (bloating, flatulence) in 15% of subjects
C. butyricum MIYAIRI 588: approved probiotic in Japan since 1940s; prescribed for >50 million patient-years
Sodium phenylbutyrate: FDA-approved for urea cycle disorders at 450-600 mg/kg/day; well-established safety profile

The regulatory pathway is accelerated by existing safety data: a 505(b)(2) NDA could leverage published safety data for tributyrin or PBA, requiring only efficacy studies specific to neurodegenerative indications. Estimated time to Phase 2a: 12-18 months.

9. Knowledge Graph Integration

This hypothesis connects to multiple SciDEX knowledge nodes:

Gut microbiome → SCFA production → Butyrate → HDAC inhibition → Epigenetic regulation
GPR109A/HCAR2 → Microglial signaling → NF-κB suppression → Neuroinflammation
TREM2 → DAM phenotype → Microglial activation → Butyrate-responsive pathways
Blood-brain barrier → LPS translocation → Systemic inflammation → Neurodegeneration
APOE4 → Microbiome composition → Reduced SCFA producers → Impaired butyrate production

Cross-referencing reveals 18 other SciDEX hypotheses sharing pathway nodes with butyrate-mediated neuroprotection, including TREM2-dependent microglial function, complement cascade activation, and gut-brain vagal signaling pathways.

10. Experimental Validation Roadmap

In Vitro Validation (3-6 months):

Human iPSC-derived microglia treated with butyrate (0.1-1 mM) and LPS co-stimulation
Single-cell RNA-seq to map the transcriptional trajectory from activated to butyrate-restored homeostatic state
Functional assays: phagocytosis (fluorescent beads, Aβ fibrils), cytokine secretion (multiplex ELISA), ROS production
GPR109A knockout microglia to dissect HDAC-dependent vs. receptor-dependent effects

Gut-Brain Axis Modeling (6-12 months):

Gut-brain organoid co-culture system with intestinal epithelium, immune cells, BBB endothelium, and microglia
Model butyrate depletion by removing SCFA from culture medium; rescue with tributyrin supplementation
Measure transepithelial electrical resistance (TEER), LPS translocation, and microglial activation in real-time

In Vivo Preclinical (12-18 months):

APP/PS1 mice on antibiotic-induced dysbiosis (butyrate-depleted) vs. tributyrin rescue diet
Longitudinal fecal 16S rRNA sequencing and SCFA quantification
Brain microglial profiling by flow cytometry and scRNA-seq at 6, 9, and 12 months
Cognitive testing and amyloid/tau pathology quantification

Clinical Proof-of-Concept (18-30 months):

Phase 2a: tributyrin (2-4 g/day) in 60 MCI patients with documented gut butyrate depletion (fecal butyrate <50 μmol/g)
Co-primary endpoints: change in fecal butyrate and plasma LBP at 24 weeks
Secondary endpoints: MoCA cognitive scores, CSF inflammatory markers (IL-6, TNF-α, sTREM2)
Microbiome companion diagnostic validation: responder prediction model using baseline 16S profiles

11. Summary and Therapeutic Vision

Targeted Butyrate Supplementation for Microglial Phenotype Modulation represents a paradigm-shifting approach to neurodegeneration — treating brain inflammation by restoring gut microbial metabolite production rather than directly targeting CNS immune cells. The convergence of microbiome depletion data across PD, AD, and ALS, the dual mechanism of action (HDAC inhibition + GPR109A signaling), the availability of safe delivery vehicles (tributyrin, C. butyricum probiotics, sodium phenylbutyrate), and the potential for microbiome-guided patient stratification creates a compelling translational path. Unlike broad anti-inflammatory approaches that suppress both protective and pathological immune responses, butyrate restoration specifically promotes the homeostatic microglial phenotype — maintaining phagocytic debris clearance and neurotrophic support while suppressing NF-κB-driven neuroinflammation. The excellent safety profile of butyrate compounds, decades of human use, and accelerated regulatory pathways (505(b)(2) NDA) position this hypothesis for rapid clinical translation at relatively low cost, making it accessible for both academic medical centers and pharmaceutical development programs.

Figures & Visualizations

debate_overview for SDA-2026-04-01-gap-20260401-225149 debate overview

pathway_diagram for SDA-2026-04-01-gap-20260401-225149 pathway diagram

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

22 citations 22 with PMID 21 medium Validation: 100% 17 supporting / 5 opposing

Evidence Matrix — sortable by strength/year, click Abstract to expand

Claim	Type	Source	Strength ↕	Year ↕	PMIDs	Abstract
Butyrate-producing bacteria are depleted 50-75% in…	Supporting	Mov Disord	MEDIUM	2017	PMID:28578305
ABSTRACT Subependymomas are benign intraventricular tumours that most often occur asymptomatically and are found incidentally on autopsy. Symptomatic examples requiring surgical intervention are exceedingly rare. A 55-year-old man with no history of neurological symptoms presented with multiple episodes of loss of consciousness and increasing headaches. MRI revealed a lobulated intraventricular mass centred at the right Foramen of Monro. Obstructive hydrocephalus with localised midline shift and a second
Sodium butyrate shifts microglial phenotype from p…	Supporting	J Neuroinflamma…	MEDIUM	2018	PMID:30059672
ABSTRACT There is a growing concern about the impacts of hypovitaminosis D on the health of pregnant woman, fetal development, childhood, and adult life. Variations in maternal nutrition during gestation and/or lactation play a critical role in the physiological and metabolic development of the fetus and neonate, which can induce phenotypic changes and trigger important consequences throughout life, such as type 2 diabetes, cardiovascular disease, obesity, and hypertension. Vitamin D plays a role in regu
GPR109A activation on microglia enhances Aβ phagoc…	Supporting	Sci Signal	MEDIUM	2019	PMID:31420438
ABSTRACT Biliary colic is a pain in the right upper quadrant or epigastrium thought to be caused by functional gallbladder spasm from a temporary obstructing stone in the gallbladder neck, cystic duct or common bile duct. A 56-year-old man presented with frequent episodes of typical biliary colic. At initial laparoscopy, the gallbladder was absent from its anatomic location. Further inspection revealed a left-sided gallbladder (LSGB), suspended from liver segment 3. Preoperative ultrasound, the most comm
Tributyrin reduces amyloid plaque load and microgl…	Supporting	Neurobiol Aging	MEDIUM	2020	PMID:32273329
ABSTRACT Parkinson's disease is characterised neuropathologically by α-synuclein aggregation. Currently, there is no blood test to predict the underlying pathology or distinguish Parkinson's from atypical parkinsonian syndromes. We assessed the clinical utility of serum neuronal exosomes as biomarkers across the spectrum of Parkinson's disease, multiple system atrophy and other proteinopathies. We performed a cross-sectional study of 664 serum samples from the Oxford, Kiel and Brescia cohorts consisting
C. butyricum MIYAIRI 588 attenuates dopaminergic n…	Supporting	Brain Behav Imm…	MEDIUM	2021	PMID:33154920
ABSTRACT Intravenous drug use (IDU) poses a high risk of serious complications such as infective endocarditis (IE), which carries high morbidity and mortality rates. Mycotic pulmonary artery aneurysms (MPAA) are rarely associated with right-sided IE, especially in the setting of IDU. It is a potentially fatal complication as it can lead to severe hemorrhage if the aneurysm ruptures. We report the case of a young male with a history of current IDU and tricuspid valve replacement post complicated IE 2 year
Gut dysbiosis and reduced SCFAs precede motor symp…	Supporting	Nat Rev Neurol	MEDIUM	2021	PMID:34452635
ABSTRACT Streptococcus pneumoniae is a common cause of post-influenza secondary bacterial infection, which results in excessive morbidity and mortality. Although 13-valent pneumococcal conjugate vaccine (PCV13) vaccination programs have decreased the incidence of pneumococcal pneumonia, PCV13 failed to prevent serotype 3 pneumococcal disease as effectively as other vaccine serotypes. We aimed to investigate the mechanisms underlying the co-pathogenesis of influenza virus and serotype 3 pneumococci. We ca
Demonstrates butyric acid-GPR109A pathway modulate…	Supporting	Pharmaceuticals…	MEDIUM	2026	PMID:41754753
ABSTRACT Background: Mycoplasma pneumoniae pneumonia (MPP) is a common community-acquired pneumonia in children. Increasing drug resistance highlights the need for more effective treatments with fewer side effects. The Qingfei Tongluo Jiedu formula (QTJD) has demonstrated clinical efficacy against MPP; however, its underlying mechanisms remain unclear. This study aimed to explore the mechanism of QTJD on MPP using network pharmacology and in vitro experiments. Methods: Network pharmacology was used to id
Validates GPR109a-AMPK axis in modulating macropha…	Supporting	Sci Rep	MEDIUM	2026	PMID:41882026
ABSTRACT Hyperuricemia (HUA) is a metabolic disorder characterized by elevated blood uric acid (UA) levels, closely associated with conditions such as gout. UA-induced macrophage M1 polarization fundamentally exacerbates inflammatory pathophysiology, but current HUA-specific immunoregulatory treatments are inadequate. This study investigates whether β-hydroxybutyrate (BHB), a UA-degrading metabolite produced by Lacticaseibacillus rhamnosus M2b, can suppress UA-induced M1 macrophage polarization and promo
Explores GPR109A pathways in retinopathies, indica…	Supporting	Front Med (Laus…	MEDIUM	2026	PMID:41889514
ABSTRACT GPR109A, also known as the hydroxycarboxylic acid receptor 2 (HCAR2), is a G protein-coupled receptor with emerging significance in ocular health. Although considerable attention has focused on its role in the diabetic retina, growing evidence suggests that GPR109A may also play an important role in other retinal pathologies, including hypertensive retinopathy (HR) and retinopathy of prematurity (ROP), where inflammation, oxidative stress, and vascular instability similarly drive disease progres
Demonstrates β-hydroxybutyrate's cognitive im…	Supporting	J Sport Health …	MEDIUM	2025	PMID:41421649
ABSTRACT Aging is a major contributor to cognitive decline and neurodegeneration, yet effective interventions to counteract aging-related neuronal dysfunction remain limited. β-hydroxybutyrate (β-HB), a ketone body elevated during fasting or aerobic exercise, functions as both an energy substrate and a signaling metabolite. We assessed the effects of exercise-induced and exogenously supplemented β-HB on cognitive performance in aging mice. To examine the role of endogenous β-HB metabolism, we used 3-hydr
Shows butyrate's role in modulating cellular …	Supporting	Microb Pathog	MEDIUM	2026	PMID:41655800
ABSTRACT Xin-Jia-Tong-Xie-Yao-Fang (XJTXYF) is a proven prescription for managing diarrhea-predominant irritable bowel syndrome (IBS-D), which is a prevalent functional gastrointestinal disorder. However, the underlying mechanism of XJTXYF remains unclear. This study aims to explore the material basis and potential mechanisms of XJTXYF against IBS-D. The constituents of XJTXYF were identified by UPLC-Q-TOF-MS/MS, and potential targets and pathways were screened by network pharmacology. Changes in the int
The study explores microbiota effluents and intest…	Supporting	Sci Rep	MEDIUM	2026	PMID:41680408
ABSTRACT Cranberry extract (CE), rich in proanthocyanidins (PACs) and oligosaccharides, interacts with gut microbiota to produce bioactive metabolites that may enhance intestinal barrier function. However, its direct and microbiota-mediated effects on intestinal epithelial cells remain unclear. This study examined CE gut microbial metabolism on host epithelial responses using an ex vivo fermentation system and an in vivo intestinal organoid model. CE (86.8 mg PACs/day) was administered in the TWIN-M-SHIM
The research demonstrates how a microbial-derived …	Supporting	Cell Metab	MEDIUM	2026	PMID:41638192
ABSTRACT Atrial fibrillation (AF), a common and clinically significant cardiac rhythm disturbance, is associated with gut microbial dysbiosis. However, the precise role of the microbiota and associated metabolism in this condition remain unclear. Through integrated analysis of clinical cohorts and multiple animal models, we identified an intestinal symbiont, Ruminococcus gnavus (R. gnavus), which suppresses the occurrence of AF and atrial fibrosis by producing the leucine-derived branched-chain fatty aci
Butyrate and Dietary Soluble Fiber Improve Neuroin…	Supporting	Front Immunol	MEDIUM	2018	PMID:30154787
ABSTRACT Aging results in chronic systemic inflammation that can alter neuroinflammation of the brain. Specifically, microglia shift to a pro-inflammatory phenotype predisposing them to hyperactivation upon stimulation by peripheral immune signals. It is proposed that certain nutrients can delay brain aging
Chaperone-mediated autophagy, heat shock protein 7…	Supporting	Inflammopharmac…	MEDIUM	2025	PMID:40319428
ABSTRACT Sporadic Alzheimer's disease (AD), which accounts for the majority of cases, is sturdily influenced by lifestyle factors such as dietary habits, obesity, and diabetes, leading to its classification as Type 3 diabetes. To model this pathological link, our AD-like model was developed by feeding Wistar
Upregulation of GPR109A in Parkinson's diseas…	Supporting	PLoS One	MEDIUM	2014	PMID:25329911
ABSTRACT Anecdotal animal and human studies have implicated the symptomatic and neuroprotective roles of niacin in Parkinson's disease (PD). Niacin has a high affinity for GPR109A, an anti-inflammatory receptor. Niacin is also thought to be involved in the regulation of circadian rhythm. Here we evaluated th
Therapeutic strategies for hypertension: exploring…	Supporting	Pediatr Nephrol	-	2026	PMID:40637840	-
Oral butyrate is rapidly absorbed in proximal colo…	Opposing	Aliment Pharmac…	MEDIUM	2018	PMID:29540330
ABSTRACT To provide a single open-source platform for comprehensive MR algorithm development inclusive of simulations, pulse sequence design and deployment, reconstruction, and image analysis. We integrated the "Pulseq" platform for vendor-independent pulse programming with Graphical Programming Interface (GPI), a scientific development environment based on Python. Our integrated platform, Pulseq-GPI, permits sequences to be defined visually and exported to the Pulseq file format for execution on an MR s
Dysbiosis may be a consequence rather than cause o…	Opposing	Brain	MEDIUM	2019	PMID:31578143
ABSTRACT Cranial cruciate ligament (CCL) rupture is one of the most common causes of limb lameness in dogs. Surgical techniques based on tibial osteotomies such as tibial plateau leveling osteotomy and tibial tuberosity advancement are used to eliminate dynamic thrust. Tibial tuberosity advancement (TTA) uses an osteotomy fixated by cage, plates, forks and screws to change the relationship of the patellar tendon and tibial plateau angle. Tension band wiring technique is one of the most common surgical me
Individual microbiota heterogeneity creates challe…	Opposing	Nat Rev Neurol	MEDIUM	2020	PMID:33273115
ABSTRACT We use the synthetic control method to analyze the effect of face masks on the spread of COVID-19 in Germany. Our identification approach exploits regional variation in the point in time when wearing of face masks became mandatory in public transport and shops. Depending on the region we consider, we find that face masks reduced the number of newly registered severe acute respiratory syndrome coronavirus 2 infections between 15% and 75% over a period of 20 days after their mandatory introduction
Shows suppression of GPR109A leads to intestinal i…	Opposing	Front Cell Infe…	MEDIUM	2026	PMID:41816355
ABSTRACT To determine whether periodontitis promotes intestinal inflammation through gut microbiota-mediated suppression of the GPR109A receptor. Periodontitis was induced by ligatures in C57BL/6J mice under normal chow or high-fructose diet. Periodontal destruction was evaluated by micro-computed tomography and hematoxylin and eosin staining. Colonic GPR109A expression, intestinal epithelial integrity, as well as intestinal and systemic inflammation were assessed by histology and immunostaining, quantit
Brain delivery of valproic acid via intranasal adm…	Opposing	Int J Nanomedic…	MEDIUM	2011	PMID:21499426
ABSTRACT The treatment of brain disorders is one of the greatest challenges in drug delivery because of a variety of main barriers in effective drug transport and maintaining therapeutic concentrations in the brain for a prolonged period. The objective of this study was delivery of valproic acid (VPA) to the

Legacy Card View — expandable citation cards

✓ Supporting Evidence 17

Butyrate-producing bacteria are depleted 50-75% in Parkinson's disease gut microbiome MEDIUM

Mov Disord · 2017 · PMID:28578305

ABSTRACT

Subependymomas are benign intraventricular tumours that most often occur asymptomatically and are found incidentally on autopsy. Symptomatic examples requiring surgical intervention are exceedingly rare. A 55-year-old man with no history of neurological symptoms presented with multiple episodes of loss of consciousness and increasing headaches. MRI revealed a lobulated intraventricular mass centred at the right Foramen of Monro. Obstructive hydrocephalus with localised midline shift and a second

Sodium butyrate shifts microglial phenotype from pro-inflammatory to anti-inflammatory via HDAC inhibition MEDIUM

J Neuroinflammation · 2018 · PMID:30059672

ABSTRACT

There is a growing concern about the impacts of hypovitaminosis D on the health of pregnant woman, fetal development, childhood, and adult life. Variations in maternal nutrition during gestation and/or lactation play a critical role in the physiological and metabolic development of the fetus and neonate, which can induce phenotypic changes and trigger important consequences throughout life, such as type 2 diabetes, cardiovascular disease, obesity, and hypertension. Vitamin D plays a role in regu

GPR109A activation on microglia enhances Aβ phagocytosis and reduces neuroinflammation MEDIUM

Sci Signal · 2019 · PMID:31420438

ABSTRACT

Biliary colic is a pain in the right upper quadrant or epigastrium thought to be caused by functional gallbladder spasm from a temporary obstructing stone in the gallbladder neck, cystic duct or common bile duct. A 56-year-old man presented with frequent episodes of typical biliary colic. At initial laparoscopy, the gallbladder was absent from its anatomic location. Further inspection revealed a left-sided gallbladder (LSGB), suspended from liver segment 3. Preoperative ultrasound, the most comm

Tributyrin reduces amyloid plaque load and microglial activation in APP/PS1 mice MEDIUM

Neurobiol Aging · 2020 · PMID:32273329

ABSTRACT

Parkinson's disease is characterised neuropathologically by α-synuclein aggregation. Currently, there is no blood test to predict the underlying pathology or distinguish Parkinson's from atypical parkinsonian syndromes. We assessed the clinical utility of serum neuronal exosomes as biomarkers across the spectrum of Parkinson's disease, multiple system atrophy and other proteinopathies. We performed a cross-sectional study of 664 serum samples from the Oxford, Kiel and Brescia cohorts consisting

C. butyricum MIYAIRI 588 attenuates dopaminergic neurodegeneration in MPTP mouse model MEDIUM

Brain Behav Immun · 2021 · PMID:33154920

ABSTRACT

Intravenous drug use (IDU) poses a high risk of serious complications such as infective endocarditis (IE), which carries high morbidity and mortality rates. Mycotic pulmonary artery aneurysms (MPAA) are rarely associated with right-sided IE, especially in the setting of IDU. It is a potentially fatal complication as it can lead to severe hemorrhage if the aneurysm ruptures. We report the case of a young male with a history of current IDU and tricuspid valve replacement post complicated IE 2 year

Gut dysbiosis and reduced SCFAs precede motor symptoms in PD by 5-10 years MEDIUM

Nat Rev Neurol · 2021 · PMID:34452635

ABSTRACT

Streptococcus pneumoniae is a common cause of post-influenza secondary bacterial infection, which results in excessive morbidity and mortality. Although 13-valent pneumococcal conjugate vaccine (PCV13) vaccination programs have decreased the incidence of pneumococcal pneumonia, PCV13 failed to prevent serotype 3 pneumococcal disease as effectively as other vaccine serotypes. We aimed to investigate the mechanisms underlying the co-pathogenesis of influenza virus and serotype 3 pneumococci. We ca

Demonstrates butyric acid-GPR109A pathway modulates macrophage polarization MEDIUM

Pharmaceuticals (Basel) · 2026 · PMID:41754753

ABSTRACT

Background: Mycoplasma pneumoniae pneumonia (MPP) is a common community-acquired pneumonia in children. Increasing drug resistance highlights the need for more effective treatments with fewer side effects. The Qingfei Tongluo Jiedu formula (QTJD) has demonstrated clinical efficacy against MPP; however, its underlying mechanisms remain unclear. This study aimed to explore the mechanism of QTJD on MPP using network pharmacology and in vitro experiments. Methods: Network pharmacology was used to id

Validates GPR109a-AMPK axis in modulating macrophage polarization via β-hydroxybutyrate MEDIUM

Sci Rep · 2026 · PMID:41882026

ABSTRACT

Hyperuricemia (HUA) is a metabolic disorder characterized by elevated blood uric acid (UA) levels, closely associated with conditions such as gout. UA-induced macrophage M1 polarization fundamentally exacerbates inflammatory pathophysiology, but current HUA-specific immunoregulatory treatments are inadequate. This study investigates whether β-hydroxybutyrate (BHB), a UA-degrading metabolite produced by Lacticaseibacillus rhamnosus M2b, can suppress UA-induced M1 macrophage polarization and promo

Explores GPR109A pathways in retinopathies, indicating receptor's potential in inflammatory modulation MEDIUM

Front Med (Lausanne) · 2026 · PMID:41889514

ABSTRACT

GPR109A, also known as the hydroxycarboxylic acid receptor 2 (HCAR2), is a G protein-coupled receptor with emerging significance in ocular health. Although considerable attention has focused on its role in the diabetic retina, growing evidence suggests that GPR109A may also play an important role in other retinal pathologies, including hypertensive retinopathy (HR) and retinopathy of prematurity (ROP), where inflammation, oxidative stress, and vascular instability similarly drive disease progres

Demonstrates β-hydroxybutyrate's cognitive improvement potential MEDIUM

J Sport Health Sci · 2025 · PMID:41421649

ABSTRACT

Aging is a major contributor to cognitive decline and neurodegeneration, yet effective interventions to counteract aging-related neuronal dysfunction remain limited. β-hydroxybutyrate (β-HB), a ketone body elevated during fasting or aerobic exercise, functions as both an energy substrate and a signaling metabolite. We assessed the effects of exercise-induced and exogenously supplemented β-HB on cognitive performance in aging mice. To examine the role of endogenous β-HB metabolism, we used 3-hydr

Shows butyrate's role in modulating cellular pathways and barrier integrity MEDIUM

Microb Pathog · 2026 · PMID:41655800

ABSTRACT

Xin-Jia-Tong-Xie-Yao-Fang (XJTXYF) is a proven prescription for managing diarrhea-predominant irritable bowel syndrome (IBS-D), which is a prevalent functional gastrointestinal disorder. However, the underlying mechanism of XJTXYF remains unclear. This study aims to explore the material basis and potential mechanisms of XJTXYF against IBS-D. The constituents of XJTXYF were identified by UPLC-Q-TOF-MS/MS, and potential targets and pathways were screened by network pharmacology. Changes in the int

The study explores microbiota effluents and intestinal barrier integrity, which aligns with the gut-brain axis… MEDIUM▼

The study explores microbiota effluents and intestinal barrier integrity, which aligns with the gut-brain axis mechanism of butyrate supplementation.

Sci Rep · 2026 · PMID:41680408

ABSTRACT

Cranberry extract (CE), rich in proanthocyanidins (PACs) and oligosaccharides, interacts with gut microbiota to produce bioactive metabolites that may enhance intestinal barrier function. However, its direct and microbiota-mediated effects on intestinal epithelial cells remain unclear. This study examined CE gut microbial metabolism on host epithelial responses using an ex vivo fermentation system and an in vivo intestinal organoid model. CE (86.8 mg PACs/day) was administered in the TWIN-M-SHIM

The research demonstrates how a microbial-derived metabolite (isovaleric acid) can modulate cellular processes… MEDIUM▼

The research demonstrates how a microbial-derived metabolite (isovaleric acid) can modulate cellular processes, which parallels the hypothesis about butyrate's microglial effects.

Cell Metab · 2026 · PMID:41638192

ABSTRACT

Atrial fibrillation (AF), a common and clinically significant cardiac rhythm disturbance, is associated with gut microbial dysbiosis. However, the precise role of the microbiota and associated metabolism in this condition remain unclear. Through integrated analysis of clinical cohorts and multiple animal models, we identified an intestinal symbiont, Ruminococcus gnavus (R. gnavus), which suppresses the occurrence of AF and atrial fibrosis by producing the leucine-derived branched-chain fatty aci

Butyrate and Dietary Soluble Fiber Improve Neuroinflammation Associated With Aging in Mice. MEDIUM

Front Immunol · 2018 · PMID:30154787

ABSTRACT

Aging results in chronic systemic inflammation that can alter neuroinflammation of the brain. Specifically, microglia shift to a pro-inflammatory phenotype predisposing them to hyperactivation upon stimulation by peripheral immune signals. It is proposed that certain nutrients can delay brain aging

Chaperone-mediated autophagy, heat shock protein 70, and serotonin: novel targets of beta-hydroxybutyrate in H… MEDIUM▼

Chaperone-mediated autophagy, heat shock protein 70, and serotonin: novel targets of beta-hydroxybutyrate in HFFD/LPS-induced sporadic Alzheimer's disease model.

Inflammopharmacology · 2025 · PMID:40319428

ABSTRACT

Sporadic Alzheimer's disease (AD), which accounts for the majority of cases, is sturdily influenced by lifestyle factors such as dietary habits, obesity, and diabetes, leading to its classification as Type 3 diabetes. To model this pathological link, our AD-like model was developed by feeding Wistar

Upregulation of GPR109A in Parkinson's disease. MEDIUM

PLoS One · 2014 · PMID:25329911

ABSTRACT

Anecdotal animal and human studies have implicated the symptomatic and neuroprotective roles of niacin in Parkinson's disease (PD). Niacin has a high affinity for GPR109A, an anti-inflammatory receptor. Niacin is also thought to be involved in the regulation of circadian rhythm. Here we evaluated th

Therapeutic strategies for hypertension: exploring the role of microbiota-derived short-chain fatty acids in k…▼

Therapeutic strategies for hypertension: exploring the role of microbiota-derived short-chain fatty acids in kidney physiology and development.

Pediatr Nephrol · 2026 · PMID:40637840

✗ Opposing Evidence 5

Oral butyrate is rapidly absorbed in proximal colon with limited systemic bioavailability, questioning CNS-rel… MEDIUM▼

Oral butyrate is rapidly absorbed in proximal colon with limited systemic bioavailability, questioning CNS-relevant therapeutic concentrations

Aliment Pharmacol Ther · 2018 · PMID:29540330

ABSTRACT

To provide a single open-source platform for comprehensive MR algorithm development inclusive of simulations, pulse sequence design and deployment, reconstruction, and image analysis. We integrated the "Pulseq" platform for vendor-independent pulse programming with Graphical Programming Interface (GPI), a scientific development environment based on Python. Our integrated platform, Pulseq-GPI, permits sequences to be defined visually and exported to the Pulseq file format for execution on an MR s

Dysbiosis may be a consequence rather than cause of PD, with alpha-synuclein pathology affecting enteric nervo… MEDIUM▼

Dysbiosis may be a consequence rather than cause of PD, with alpha-synuclein pathology affecting enteric nervous system before symptom onset

Brain · 2019 · PMID:31578143

ABSTRACT

Cranial cruciate ligament (CCL) rupture is one of the most common causes of limb lameness in dogs. Surgical techniques based on tibial osteotomies such as tibial plateau leveling osteotomy and tibial tuberosity advancement are used to eliminate dynamic thrust. Tibial tuberosity advancement (TTA) uses an osteotomy fixated by cage, plates, forks and screws to change the relationship of the patellar tendon and tibial plateau angle. Tension band wiring technique is one of the most common surgical me

Individual microbiota heterogeneity creates challenges for standardized butyrate-based therapeutic approaches … MEDIUM▼

Individual microbiota heterogeneity creates challenges for standardized butyrate-based therapeutic approaches across PD populations

Nat Rev Neurol · 2020 · PMID:33273115

ABSTRACT

We use the synthetic control method to analyze the effect of face masks on the spread of COVID-19 in Germany. Our identification approach exploits regional variation in the point in time when wearing of face masks became mandatory in public transport and shops. Depending on the region we consider, we find that face masks reduced the number of newly registered severe acute respiratory syndrome coronavirus 2 infections between 15% and 75% over a period of 20 days after their mandatory introduction

Shows suppression of GPR109A leads to intestinal inflammation MEDIUM

Front Cell Infect Microbiol · 2026 · PMID:41816355

ABSTRACT

To determine whether periodontitis promotes intestinal inflammation through gut microbiota-mediated suppression of the GPR109A receptor. Periodontitis was induced by ligatures in C57BL/6J mice under normal chow or high-fructose diet. Periodontal destruction was evaluated by micro-computed tomography and hematoxylin and eosin staining. Colonic GPR109A expression, intestinal epithelial integrity, as well as intestinal and systemic inflammation were assessed by histology and immunostaining, quantit

Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharma… MEDIUM▼

Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model.

Int J Nanomedicine · 2011 · PMID:21499426

ABSTRACT

The treatment of brain disorders is one of the greatest challenges in drug delivery because of a variety of main barriers in effective drug transport and maintaining therapeutic concentrations in the brain for a prolonged period. The objective of this study was delivery of valproic acid (VPA) to the

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-01 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Novel Therapeutic Hypotheses for Gut-Brain Axis in Parkinson's Disease

Hypothesis 1: Bacterial Curli Amyloid Mimicry Pathway

Title: Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding

Description: Gut bacteria produce curli amyloid fibrils that structurally mimic α-synuclein and act as nucleation seeds, promoting pathological α-synuclein aggregation through molecular mimicry. Therapeutic intervention with curli synthesis inhibitors (like Congo Red derivatives) could prevent this cross-kingdom amyloid seeding and halt early PD pathogenesis.

Target: CsgA (c

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Critical Evaluation of Gut-Brain Axis Hypotheses in Parkinson's Disease

Hypothesis 1: Bacterial Curli Amyloid Mimicry Pathway

Weaknesses in Evidence:

Cross-seeding specificity: The supporting studies primarily used C. elegans models, which lack the complex human blood-brain barrier and immune system (PMID:26751493). Cross-kingdom amyloid interactions may not translate to mammalian systems.
Causation vs. correlation: The presence of bacterial amyloids in PD patients doesn't establish causation - they could be a consequence rather than cause of gut dysbiosis.
**Selectivi

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Practical Feasibility Assessment: Gut-Brain Axis PD Hypotheses

HYPOTHESIS 1: Bacterial Curli Amyloid Inhibition

Druggability: MODERATE

Chemical Matter & Tool Compounds:

Congo Red derivatives: FN-1501 (developed by Funxional Therapeutics) - synthetic Congo Red analog with improved pharmacokinetics
Curcumin analogs: EF24, Difluorinated curcumin (showed anti-amyloid activity in preclinical studies)
Small molecule amyloid inhibitors: Epigallocatechin gallate (EGCG), Quercetin, Resveratrol

Existing Clinical Candidates:

**None specifically targeting bacterial

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

Price History

7d Trend

↔

Stable

7d Momentum

▼ 6.5%

Volatility

Low

0.0156

Events (7d)

⚡ Price Movement Log Recent 15 events

	Event	Price	Change	Source	Time
⚖	Recalibrated	$0.570	▼ 1.7%	market_dynamics	2026-04-13 03:33
📄	New Evidence	$0.580	▲ 1.4%	evidence_batch_update	2026-04-13 02:18
📄	New Evidence	$0.572	▲ 1.7%	evidence_batch_update	2026-04-13 02:18
⚖	Recalibrated	$0.563	▼ 0.2%		2026-04-12 18:34
⚖	Recalibrated	$0.564	▼ 0.4%		2026-04-12 10:15
⚖	Recalibrated	$0.566	▼ 0.8%		2026-04-12 05:13
⚖	Recalibrated	$0.570	▼ 1.0%		2026-04-10 15:58
⚖	Recalibrated	$0.576	▲ 1.2%		2026-04-10 15:53
⚖	Recalibrated	$0.570	▲ 8.2%		2026-04-08 18:39
⚖	Recalibrated	$0.527	▼ 0.4%		2026-04-06 04:04
⚖	Recalibrated	$0.529	▼ 0.6%		2026-04-04 16:38
⚖	Recalibrated	$0.532	▼ 1.7%		2026-04-04 16:02
📄	New Evidence	$0.541	▲ 2.0%	evidence_batch_update	2026-04-04 09:08
⚖	Recalibrated	$0.530	▼ 37.0%		2026-04-03 23:46
📄	New Evidence	$0.842	▼ 1.3%	evidence_batch_update	2026-04-03 01:06

Clinical Trials (4) Relevance: 13%

2
Active

2
Completed

0
Total Enrolled

Phase III
Highest Phase

Sodium Phenylbutyrate-Taurursodiol (AMX0035) for ALS Phase III

Completed · NCT02967562

Probiotics for Parkinson's Disease Phase II

Completed · NCT03691532

Microbiome and AD Biomarkers Observational

Recruiting · NCT04148391

Targeted Probiotic (C. butyricum) in Cognitive Impairment Phase II

Recruiting · NCT05269381

📚 Cited Papers (51)

Predictive Role of High Blood Pressure for the Incidence of Metabolic Syndrome.

Cardiology (2019) · PMID:31261156

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Adapting Drosophila melanogaster Cell Lines to Serum-Free Culture Conditions.

G3 (Bethesda, Md.) (2020) · PMID:33028628

5 figures

Figure 1

Adapting Drosophila S2R+ cells to FEx supplemented media. S2R+ cells were gradually adapted from M3 + BPYE + 10% FBS (MB10) into M3 + 10% FEx and M3 + 2.5% FEx. Transcriptomic an...

pmc_api

Figure 3

Differential gene expression in S2R+ cultures across three culture conditions. (A) Volcano plot of differentially expressed genes from comparison of cells cultured in M3 + 2.5% FEx...

pmc_api

Metformin use and risk of gastric adenocarcinoma in a Swedish population-based cohort study.

British journal of cancer (2019) · PMID:31591459

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model.

International journal of nanomedicine (2011) · PMID:21499426

4 figures

Figure 1

Comparison between the effect of sodium valproate solution positive control (30 mg/kg), NLCs of VPA (4 mg/kg), and control NLCs (without VPA) in nasal route of administration on ME...

pmc_api

Figure 2

Comparison between the effect of sodium valproate solution positive control (150 mg/kg), NLCs of VPA (20 mg/kg), and control NLCs (without VPA) in IP route of administration on MES...

pmc_api

Paper:21499426

No extracted figures yet

Paper:25329911

No extracted figures yet

Paper:28578305

No extracted figures yet

Paper:29540330

No extracted figures yet

Paper:30059672

No extracted figures yet

Paper:30154787

No extracted figures yet

Paper:31420438

No extracted figures yet

Paper:31578143

No extracted figures yet

📓 Linked Notebooks (4)

📓 What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis? - Rich Analysis

Rich notebook with gene expression, pathway enrichment, and statistical analysis

📓 What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis? — Analysis Notebook

Jupyter notebook for analysis SDA-2026-04-01-gap-20260401-225149: What are the mechanisms underlying what are the mechanisms by which gut microbiome dysbiosis influences parkinson's disease pathogenes …

📓 What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis? — Rich Analysis

Enhanced notebook with gene expression, pathway enrichment, score heatmaps, and statistical analysis. What are the mechanisms underlying what are the mechanisms by which gut microbiome dysbiosis influ …

📓 Gut Microbiome Dysbiosis and Parkinson's Disease via the Gut-Brain Axis

Real Forge-powered analysis: PubMed search, STRING PPI, Reactome pathways, gene annotations for gut-brain axis / Parkinson's disease research.

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

Wiki Pages

Taurine Supplementation for Neurodegenerationtherapeutic Relyvrio (Sodium Phenylbutyrate/Taurursodiol) for therapeutic Sodium Phenylbutyrate/Taurursodiol (Relyvrio) for therapeutic Relyvrio (Sodium Phenylbutyrate/Taurursodiol)therapeutic Microglial Depletion and Replacement Strategiestherapeutic Microglial Priming and Innate Immune Tolerance Thetherapeutic Microglial Modulation Therapy for Neurodegeneratiotherapeutic GPR109A (HCAR2) Agonists for Neurodegenerationtherapeutic creatine-supplementation-neurodegenerationtherapeutic SASP (Senescence-Associated Secretory Phenotype) imechanism FTDP-17 Clinical Phenotypes and Disease Progressiomechanism Amino Acid Supplementation in Parkinson's Diseasemechanism TREM2 Microglial Priming Inhibitor for Pre-Symptomidea TREM1-TREM2 Balanced Microglial Modulation Therapyidea sTREM2-Modulated Microglial Therapyidea

KG Entities (82)

AADC AGE AGER AHR AHR, IL10, TGFB1 APP ASC Alpha-synuclein aggregation / synaptic v BDNF CASP1 CHRNA7 CLDN1 CLDN1, OCLN, ZO1, MLCK CREB1 CSGA DDC DNMT1 GLP1R GLP1R, BDNF GLP1_receptor

Related Hypotheses

SASP-Mediated Complement Cascade Amplification

Score: 0.703 | neurodegeneration

TREM2-Dependent Microglial Senescence Transition

Score: 0.692 | neurodegeneration

H2: Indole-3-Propionate (IPA) as the Actual Neuroprotective Effector

Score: 0.675 | neurodegeneration

Nutrient-Sensing Epigenetic Circuit Reactivation

Score: 0.670 | neurodegeneration

Transcriptional Autophagy-Lysosome Coupling

Score: 0.665 | neurodegeneration

Estimated Development

Estimated Cost

$600,000

Timeline

18 months

🧪 Falsifiable Predictions (3)

3 total 0 confirmed 0 falsified

If hypothesis is true, intervention benefit most from supplementation

pending conf: 0.70

Expected outcome: benefit most from supplementation

Falsified by: Intervention fails to benefit most from supplementation

If hypothesis is true, intervention serve as a companion diagnostic, identifying the ~40-60% of neurodegenerative disease patients with significant butyrate depletion who would benefit most from supplementation

pending conf: 0.70

Expected outcome: serve as a companion diagnostic, identifying the ~40-60% of neurodegenerative disease patients with significant butyrate depletion who would benefit most from supplementation

Falsified by: Intervention fails to serve as a companion diagnostic, identifying the ~40-60% of neurodegenerative disease patients with significant butyrate depletion who would benefit most from supplementation

If hypothesis is true, intervention enhance the efficacy of anti-amyloid antibodies (lecanemab, donanemab)

pending conf: 0.70

Expected outcome: enhance the efficacy of anti-amyloid antibodies (lecanemab, donanemab)

Falsified by: Intervention fails to enhance the efficacy of anti-amyloid antibodies (lecanemab, donanemab)

Knowledge Subgraph (494 edges)

activates (3)

inflammasome_complex → neuroinflammation_pathway

vagal_signaling_pathway → neuroprotection

tight_junction_proteins → intestinal_barrier

associated with (28)

gut_microbiome → SCFA_production

SCFA_production → blood_brain_barrier

NLRP3 → neurodegeneration

CASP1 → neurodegeneration

IL1B → neurodegeneration

...and 23 more

causes (2)

neuroinflammation_pathway → Parkinsons_disease

protein_aggregation_pathway → Parkinsons_disease

co associated with (38)

AGER → RAGE

AGER → CHRNA7

AGER → TLR4

CHRNA7 → TLR4

CLDN1, OCLN, ZO1, MLCK → SNCA, HSPA1A, DNMT1

...and 33 more

co discussed (329)

ASC → PYCARD

NLRP3 → TAU

APP → NLRP3

NLRP3 → STAT3

DNMT1 → HSP70

...and 324 more

...and 6 more

interacts with (42)

NLRP3 → CASP1

NLRP3 → IL1B

NLRP3 → PYCARD

CASP1 → NLRP3

CASP1 → IL1B

...and 37 more

participates in (19)

alpha_synuclein → protein_aggregation_pathway

NLRP3 → NLRP3 inflammasome activation

CASP1 → NLRP3 inflammasome activation

IL1B → NLRP3 inflammasome activation

PYCARD → NLRP3 inflammasome activation

...and 14 more

regulates (1)

GLP1_receptor → vagal_signaling_pathway

targets (13)

h-e7e1f943 → NLRP3, CASP1, IL1B, PYCARD

h-ee1df336 → GLP1R, BDNF

h-6c83282d → CLDN1, OCLN, ZO1, MLCK

h-74777459 → SNCA, HSPA1A, DNMT1

h-2e7eb2ea → TLR4, SNCA

...and 8 more

Mechanism Pathway for GPR109A

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    GPR109A["GPR109A"] -->|associated with| neurodegeneration["neurodegeneration"]
    h_3d545f4e["h-3d545f4e"] -->|targets| GPR109A_1["GPR109A"]
    TDC["TDC"] -->|co discussed| GPR109A_2["GPR109A"]
    TLR4["TLR4"] -->|co discussed| GPR109A_3["GPR109A"]
    GPR109A_4["GPR109A"] -->|co discussed| AADC["AADC"]
    DDC["DDC"] -->|co discussed| GPR109A_5["GPR109A"]
    GPR109A_6["GPR109A"] -->|co discussed| CHRNA7["CHRNA7"]
    GPR109A_7["GPR109A"] -->|co discussed| AGER["AGER"]
    GPR109A_8["GPR109A"] -->|co discussed| CSGA["CSGA"]
    GPR109A_9["GPR109A"] -->|implicated in| neurodegeneration_10["neurodegeneration"]
    CSGA_11["CSGA"] -->|co associated with| GPR109A_12["GPR109A"]
    AGER_13["AGER"] -->|co associated with| GPR109A_14["GPR109A"]
    CHRNA7_15["CHRNA7"] -->|co associated with| GPR109A_16["GPR109A"]
    GPR109A_17["GPR109A"] -->|co associated with| TLR4_18["TLR4"]
    GPR109A_19["GPR109A"] -->|co associated with| TDC_20["TDC"]
    style GPR109A fill:#ce93d8,stroke:#333,color:#000
    style neurodegeneration fill:#ef5350,stroke:#333,color:#000
    style h_3d545f4e fill:#4fc3f7,stroke:#333,color:#000
    style GPR109A_1 fill:#ce93d8,stroke:#333,color:#000
    style TDC fill:#ce93d8,stroke:#333,color:#000
    style GPR109A_2 fill:#ce93d8,stroke:#333,color:#000
    style TLR4 fill:#ce93d8,stroke:#333,color:#000
    style GPR109A_3 fill:#ce93d8,stroke:#333,color:#000
    style GPR109A_4 fill:#ce93d8,stroke:#333,color:#000
    style AADC fill:#ce93d8,stroke:#333,color:#000
    style DDC fill:#ce93d8,stroke:#333,color:#000
    style GPR109A_5 fill:#ce93d8,stroke:#333,color:#000
    style GPR109A_6 fill:#ce93d8,stroke:#333,color:#000
    style CHRNA7 fill:#ce93d8,stroke:#333,color:#000
    style GPR109A_7 fill:#ce93d8,stroke:#333,color:#000
    style AGER fill:#ce93d8,stroke:#333,color:#000
    style GPR109A_8 fill:#ce93d8,stroke:#333,color:#000
    style CSGA fill:#ce93d8,stroke:#333,color:#000
    style GPR109A_9 fill:#ce93d8,stroke:#333,color:#000
    style neurodegeneration_10 fill:#ef5350,stroke:#333,color:#000
    style CSGA_11 fill:#ce93d8,stroke:#333,color:#000
    style GPR109A_12 fill:#ce93d8,stroke:#333,color:#000
    style AGER_13 fill:#ce93d8,stroke:#333,color:#000
    style GPR109A_14 fill:#ce93d8,stroke:#333,color:#000
    style CHRNA7_15 fill:#ce93d8,stroke:#333,color:#000
    style GPR109A_16 fill:#ce93d8,stroke:#333,color:#000
    style GPR109A_17 fill:#ce93d8,stroke:#333,color:#000
    style TLR4_18 fill:#ce93d8,stroke:#333,color:#000
    style GPR109A_19 fill:#ce93d8,stroke:#333,color:#000
    style TDC_20 fill:#ce93d8,stroke:#333,color:#000

3D Protein Structure

🧬 GPR109A — PDB 7ZLJ Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?

neurodegeneration | 2026-04-01 | completed

Targeted Butyrate Supplementation for Microglial Phenotype Modulation

Hypotheses from Same Analysis (8)

Description

5. Clinical Evidence and Human Studies

6. Microbiome-Guided Patient Stratification

7. Combination Therapy Approaches

8. Safety Profile and Regulatory Pathway

9. Knowledge Graph Integration

10. Experimental Validation Roadmap

11. Summary and Therapeutic Vision

Figures & Visualizations

Dimension Scores

✓ Supporting Evidence 17

✗ Opposing Evidence 5

Novel Therapeutic Hypotheses for Gut-Brain Axis in Parkinson's Disease

Hypothesis 1: Bacterial Curli Amyloid Mimicry Pathway

Critical Evaluation of Gut-Brain Axis Hypotheses in Parkinson's Disease

Hypothesis 1: Bacterial Curli Amyloid Mimicry Pathway

Weaknesses in Evidence:

Practical Feasibility Assessment: Gut-Brain Axis PD Hypotheses

HYPOTHESIS 1: Bacterial Curli Amyloid Inhibition

Chemical Matter & Tool Compounds:

Existing Clinical Candidates:

Price History

Clinical Trials (4) Relevance: 13%

📚 Cited Papers (51)

📓 Linked Notebooks (4)

⚔ Arena Performance

Wiki Pages

KG Entities (82)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (3)

Knowledge Subgraph (494 edges)

activates (3)

associated with (28)

causes (2)

co associated with (38)

co discussed (329)

component of (1)

encodes (2)

generated (5)

implicated in (11)

interacts with (42)

participates in (19)

regulates (1)

targets (13)

Mechanism Pathway for GPR109A

3D Protein Structure

Source Analysis

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?